000			01473 a2200385 4500
005			20250513034505.0
264		0	_c19950907
008			199509s 0 0 eng d
022			_a0895-0172
024	7		_a10.1176/jnp.7.2.135 _2doi
040			_aNLM _beng _cNLM
100	1		_aKeck, P E
245	0	0	_aNeuroleptic malignant syndrome and malignant hyperthermia: end of a controversy? _h[electronic resource]
260			_bThe Journal of neuropsychiatry and clinical neurosciences _c1995
300			_a135-44 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aAnimals
650	0	4	_aAntipsychotic Agents _xadministration & dosage
650	0	4	_aCorpus Striatum _xdrug effects
650	0	4	_aDisease Models, Animal
650	0	4	_aEnergy Metabolism _xdrug effects
650	0	4	_aHumans
650	0	4	_aHypothalamus _xdrug effects
650	0	4	_aMalignant Hyperthermia _xdiagnosis
650	0	4	_aMuscle, Skeletal _xdrug effects
650	0	4	_aNeural Pathways _xdrug effects
650	0	4	_aNeuroleptic Malignant Syndrome _xdiagnosis
650	0	4	_aReceptors, Dopamine _xdrug effects
650	0	4	_aRisk Factors
650	0	4	_aSubstantia Nigra _xdrug effects
700	1		_aCaroff, S N
700	1		_aMcElroy, S L
773	0		_tThe Journal of neuropsychiatry and clinical neurosciences _gvol. 7 _gno. 2 _gp. 135-44
856	4	0	_uhttps://doi.org/10.1176/jnp.7.2.135 _zAvailable from publisher's website
999			_c7626392 _d7626392